FTC Competition Hearings: PhRMA, Former Rep. Waxman Advocate Focus On PBMs
Executive Summary
FTC is assessing possible changes to competition and consumer protection enforcement law and policy, with a hearing on Innovation and IP Policy set for Oct. 23-24.
You may also be interested in...
FTC Hearing On IP Policy: Patent Eligibility Requirements Are Top Industry Concern
Supreme Court decisions on subject matter patentability have discouraged investments, panelists tell FTC; BIO says biotech companies may look outside patent system.
Mehta Analysis: From Generics To Biosimilars – When Will History Hurry Up And Repeat Itself?
More than three decades ago, the Hatch-Waxman Act ushered in a new model of pharma industry renewal by opening the door to effective generic competition after drug patent expiry and encouraging originators to invest in innovation. Viren Mehta, founding partner of Mehta Partners LLC, would like to see similar gains from biosimilar adoption.
Mehta Analysis: From Generics To Biosimilars – When Will History Hurry Up And Repeat Itself?
More than three decades ago, the Hatch-Waxman Act ushered in a new model of pharma industry renewal by opening the door to effective generic competition after drug patent expiry and encouraging originators to invest in innovation. Viren Mehta, founding partner of Mehta Partners LLC, would like to see similar gains from biosimilar adoption.